Fibrin sealant for esophageal anastomosis: A phase II study

Table 1 Baseline patient characteristics, n (%)

Variable	n = 57
Age, yr ( median and range)	61 (41-75)
Sex
Male	49 (86.0)
Female	8 (14.0)
BMI
BMI < 24	46 (80.7)
BMI ≥ 24	11 (19.3)
Location of tumor
Upper	4 (7.0)
Middle	20 (35.1)
Lower	23 (40.4)
Esophagogastric junction	5 (8.8)
Multiple primary tumor	5 (8.8)
Histology
Squamous cell carcinoma	55 (96.5)
Adenocarcinoma	2 (3.5)
Differentiation
Poor	13 (22.8)
Moderate	33 (57.9)
Well	2 (3.5)
Unknown	9 (15.8)
Clinical T stage
cT1	3 (5.3)
cT2	19 (33.3)
cT3	34 (59.6)
cT4	1 (1.8)
Clinical N stage
N0	24 (42.1)
N1	19 (33.3)
N2	9 (15.8)
N3	5 (8.8)
Clinical stage group
I	2 (3.5)
II	28 (49.1)
III	21 (36.8)
IVA	6 (10.5)
Therapy
Surgery and neoadjuvant chemotherapy	5 (8.8)
Surgery and neoadjuvant chemoradiotherapy	17 (29.8)
Surgery alone	35 (61.4)

BMI: Body mass index.

Table 2 Distribution of pathologic stage groups after surgery, n (%)

Pathologic stage group	n = 57
Surgery alone
IB	6 (10.5)
IIA	13 (22.8)
IIB	5 (8.8)
IIIA	2 (3.5)
IIIB	8 (14.0)
IVA	1 (1.8)
Neoadjuvant therapy
I	11 (19.3)
II	1 (1.8)
IIIA	4 (7.0)
IIIB	6 (10.5)

Table 3 Postoperative complications, n (%)

Postoperative complication	n = 57
Anastomotic leakage	3 (5.3)
Esophagogastric anastomosis1	2 (3.5)
Gastric stump2	1 (1.8)
Anastomotic stricture	1 (1.8)
Arrhythmia	11 (19.3)
Laryngeal nerve injury	10 (17.5)
Pneumonia	8 (14.0)
Lymphorrhea	6 (10.5)
Heart failure	6 (10.5)
Respiratory failure	4 (7.0)
ARDS	3 (5.3)
Aerothorax	3 (5.3)
Pyothorax	1 (1.8)
Atelectasis	1 (1.8)
Chylothorax	1 (1.8)
Major complications	10 (17.5)
Minor complications	18 (31.6)

¹Full thickness gastrointestinal defects were detected at the esophagogastric anastomosis.

²Total parietal defect was detected at the staple line of gastric stump. ARDS: Acute respiratory distress syndrome.